Launxp Biomedical Co., Ltd. · TPEX:6876
Launxp Biomedical Co., Ltd. financial statements
Launxp Biomedical Co., Ltd.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.
Financials
Annual, in TWD
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | 2.48M | 11.0K | 0 | 0 |
| Cost of revenue | 199.0K | 0 | 0 | 0 |
| Gross profit | 2.29M | 11.0K | 0 | 0 |
| Research and development | 37.6M | 43.7M | 19.7M | 15.1M |
| Selling, general and administrative | 46.9M | 37.4M | 23.9M | 8.18M |
| Operating income | -82.3M | -81.0M | -43.6M | -34.8M |
| Depreciation and amortization | 2.40M | 2.41M | 2.35M | 1.60M |
| EBITDA | -79.9M | -78.6M | -41.3M | -33.2M |
| Interest expense | 42.0K | 167.0K | 195.0K | 60.0K |
| Income before tax | -82.1M | -80.9M | -43.6M | -34.7M |
| Net income | -82.6M | -80.9M | -43.6M | -34.7M |
| Earnings per share, basic | -2.55 | -2.51 | -1.35 | -1.08 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 98.4M | 179.7M | 15.2M | 34.1M | |
| Short-term investments | 27.0M | ||||
| Receivables | 0 | 9.00K | 0 | ||
| Current assets | 104.9M | 185.5M | 24.2M | 64.2M | |
| Total assets | 123.9M | 206.5M | 32.4M | 73.9M | |
| Accounts payable | 2.38M | 1.94M | 411.0K | 0 | |
| Current liabilities | 13.9M | 21.5M | 7.58M | 5.17M | |
| Total liabilities | 15.0M | 23.2M | 10.2M | 8.65M | |
| Shareholders' equity | 108.9M | 183.3M | 22.2M | 65.2M | |
| Shares outstanding | 48.0M | 32.4M | 32.2M | 32.2M | 32.2M |
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Cash from operations | -76.7M | -59.1M | -44.2M | -29.0M |
| Capital spending | -316.0K | -3.31M | -804.0K | -4.24M |
| Free cash flow | -77.0M | -62.5M | -45.0M | -33.2M |
| Change in cash | -81.4M | 164.5M | -18.9M | 2.20M |